cbdMD, Inc. YCBD
0.47
0.01
2.17%
as of 25 Sep
- Market cap
- $4.8M
- P/E
- 55.3×
Follow YCBD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 78.82 |
P/S ratio |
0.25 | 0.64 | 0.39 | 0.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.21) | (14.96) | (10.70) | (16.09) | |
P/B ratio |
0.67 | 1.35 | 0.83 | 0.87 | |
Price to Tangible BV |
0.95 | 1.72 | 1.12 | 1.18 | |
EV/Sales |
0.27 | 0.60 | 0.39 | 0.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.62) | (5.87) | (3.12) | (3.45) | |
EV/FCF |
(3.08) | (5.19) | (2.84) | (3.09) | |
Quick Ratio |
1.03 | 1.62 | 1.42 | 1.26 | |
Current Ratio |
2.05 | 2.94 | 2.82 | 2.50 | |
Net Debt/EBITDA |
8.93 | (26.00) | 6.98 | 3.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.83 | 1.64 | 1.72 | 1.82 | |
Operating CF/Net income |
0.35 | 2.50 | 0.82 | 0.37 | |
Capex/Depreciation |
(0.01) | (0.40) | (0.01) | (0.04) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.20 | 0.16 | 0.19 | 0.17 | |
Share Based Compensation of Revenue |
0.09% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.69 | 0.44 | 0.70 | 0.39 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.38 | |
Earnings Yield |
(300.12%) | (141.59%) | (12.36%) | 1.27% | |
Free Cash Flow Yield |
(35.06%) | (18.11%) | (35.26%) | (34.86%) | |
Revenue per Share |
1.17 | 0.56 | 0.54 | 0.52 | |
Operating CF per Share |
(0.06) | (0.09) | (0.07) | (0.04) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.11) | (0.07) | (0.04) | |
Cash per Share |
0.56 | 0.38 | 0.25 | 0.20 | |
Shareholders Equity per Share |
1.80 | 1.00 | 0.89 | 0.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.80 | 1.00 | 0.89 | 0.77 | |
Free Cash Flow |
(0.24) | (0.98) | (0.73) | (0.46) | |
Working Capital |
3.36 | 5.39 | 5.42 | 4.62 | |
Capital Expenditures |
0.00 | (0.16) | (0.01) | (0.02) | |
Net Current Asset Value |
3.36 | 5.39 | 5.42 | 2.76 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 | |
Net Profit Margin |
(14.40%) | (6.47%) | (15.55%) | (21.57%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.01 | 1.20 | 1.31 | 1.36 | |
Average Payables |
1.36 | 1.02 | 1.34 | 1.35 | |
Average Inventory |
2.55 | 2.55 | 2.99 | 3.04 | |
Average Assets |
10.50 | 11.66 | 11.60 | 11.52 | |
Average Common Equity |
4.59 | 5.39 | 4.97 | 7.16 |
Columns are period end dates